AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013
American Society of Clinical Oncology Annual Meeting
2013 ASCO Annual Meeting
CAMBRIDGE, Mass. & TOKYO -- May 15, 2013
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today
announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus
sOrafenib in 1^st line advanced RCC) of investigational agent tivozanib in
patients with advanced renal cell carcinoma (RCC) will be presented at the
2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking
place in Chicago, May 31 – June 4, 2013.
The schedule for tivozanib poster presentations at ASCO is as follows:
Date & Time: Monday, June 3, 2013 from 8:00 to 11:45 a.m. CT
Session: General Poster Session, Genitourinary Cancer Track
Title: Rates of Dose Adjustment in Patients Treated with Tivozanib Versus
Sorafenib in the Phase III TIVO-1 Study
Abstract Number: 4564
Location: S Hall A2, Poster Board #30H
Presenter: Thomas E. Hutson, D.O., Pharm.D.
Date & Time: Tuesday, June 4, 2013 from 8:00 a.m. to 12:00 p.m. CT; discussion
from 11:30 to 11:45 a.m. CT
Session: Poster Discussion Session, Genitourinary Cancer Track
Title: Tivozanib in Patients Treatment-Naive for Metastatic Renal Cell
Carcinoma: A Subset Analysis of the Phase III TIVO-1 Study
Abstract Number: 4513
Location: E450b, Poster Board #2
Presenter: Piotr Tomczak, M.D.
About Kidney Cancer
Advanced RCC, or kidney cancer, is the ninth most commonly diagnosed cancer in
men and women in the U.S.^1 Worldwide it is estimated that more than 250,000
people are diagnosed and more than 100,000 people die from the disease each
year.^2 RCC accounts for more than 90 percent of all kidney cancers.^3
Tivozanib is an oral, once-daily, investigational vascular endothelial growth
factor (VEGF) tyrosine kinase inhibitor for which results from a Phase 3
clinical study in advanced RCC have been reported, and is being evaluated in
About the AVEO/Astellas Collaboration
In February 2011, AVEO and Astellas entered into a worldwide agreement to
develop and commercialize tivozanib outside of Asia for the treatment of a
broad range of cancers. Subject to regulatory approval, AVEO will lead
commercialization of tivozanib in North America and Astellas will lead
commercialization of tivozanib in the European Union (EU).
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceuticals. Astellas has
approximately 17,000 employees worldwide. The organization is committed to
becoming a global category leader in Urology, Immunology (including
Transplantation) and Infectious Diseases, Oncology, Neuroscience and DM
Complications and Kidney Diseases. For more information on Astellas Pharma
Inc., please visit the company website at www.astellas.com/en.
AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to
discovering, developing and commercializing targeted therapies to impact
patients' lives. AVEO's proprietary Human Response Platform^TM provides the
company unique insights into cancer biology and is being leveraged in the
discovery and clinical development of its cancer therapeutics. For more
information, please visit the company's website at www.aveooncology.com.
^1U.S. Cancer Statistics Working Group. United States Cancer Statistics:
1999–2009 Incidence and Mortality Web-based Report. Atlanta: U.S. Department
of Health and Human Services, Centers for Disease Control and Prevention and
National Cancer Institute; 2013. Available at: ^www.cdc.gov/uscs^.
^2Cancer Research UK. Available at:
^3American Cancer Society. Available at:
Caton Morris, 910-232-7166
Rob Kloppenburg, 617-930-5595
Astellas US LLC
Jenny Kite, 224-205-5405
Press spacebar to pause and continue. Press esc to stop.